Bridgit O. Crews

Bridgit O. Crews

Auto-generated profile, based on publicly available information

Bridgit O. Crews

Washington University School of Medicine

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Clinical Chemistry
Verified
Journal Article
Closed access
YLYanchun Lin
Yanchun Lin
CFChristopher W Farnsworth
Christopher W Farnsworth
VAVahid Azimi
Vahid Azimi
DLDavid B Liss
David B Liss
MMMichael E Mullins
Michael E Mullins
BCBridgit O Crews
Bridgit O Crews
Background: The increasing prevalence of xylazine in the illicit drug supply is a growing concern for major health consequences in individuals who use fentanyl mixed with xylazine, but limited data are available regarding the pharmacokinetics of xylazine in humans. Methods: Xylazine was quantified in serial remnant plasmas collected from 28 patients starting at the initial patient encounter and continuing for up to 52 h from presentation, using LC-MS/MS to calculate the terminal half-life for xylazine. Xylazine metabolites were identified by product ion scanning, and multiple reaction monitoring was used to estimate the relative abundance of xylazine metabolites in 74 collected plasma samples. Results: The median terminal half-life for xylazine was calculated to be 12.0 h (range: 5.9–20.8). Oxo-xylazine and sulfone-xylazine metabolites were detected in all plasma specimens that contained xylazine. Conclusions: The half-life of xylazine in humans is longer than previously observed in animal studies, which furthers the current understanding of the expected duration of effects in individuals who use fentanyl mixed with xylazine and the window of detection. Both oxo-xylazine and sulfone-xylazine appear to circulate in plasma for as long as xylazine.

14 October 2025 in Bioanalysis
Verified
Journal Article
Open access
BCBridgit O. Crews
Bridgit O. Crews
Xylazine is a veterinary sedative that is frequently detected in the illicit drug supply, often found mixed with illicitly manufactured fentanyl (IMF). It has been detected in the blood of overdose victims and patients who use illicit drugs. Xylazine is not approved for use in humans. It is an alpha-2-adrenergic receptor agonist that causes deep sedation that is non-responsive to naloxone, the antidote for opioid overdose. Chronic exposure to xylazine has been linked to severe wounds that can progress to amputation. Medetomidine is another related veterinary sedative that has more recently emerged as an adulterant in IMF. Medetomidine is also an alpha-2-adrenergic agonist, and in veterinary medicine it is known to be significantly more potent than xylazine. The mixture of these drugs with IMF complicates the treatment of patients exposed to these drugs. Wider availability of analytical methods to detect xylazine, and now medetomidine, is crucial for responding to these health threats and increasing knowledge on the harms and potential therapies for exposed patients. This review covers what is currently known about these drugs, including observed concentrations in various biospecimens, expected major metabolites and windows of detection, and available analytical approaches for detecting exposure.

10 November 2023 in Journal of Analytical Toxicology
Verified
Journal Article
Closed access
PDF file
HBHannah M Brown
Hannah M Brown
SRStephen M Roper
Stephen M Roper
DDDennis J Dietzen
Dennis J Dietzen
BCBridgit O Crews
Bridgit O Crews
Current guidelines recommend universal screening for substance use disorders in obstetric patients, and neonatal drug testing is also frequently performed. Meconium is often the preferred specimen type to detect neonatal drug exposure due to a longer window of detection compared to urine, but most laboratories send out meconium testing to specialized reference laboratories, which can delay results for several days or more. Here, we evaluate a rapid and definitive liquid chromatography–tandem mass spectrometry method for neonatal urine drug testing and compare results obtained using this method to paired meconium drug testing in 1,424 neonates for amphetamines, cocaine, cannabinoids, opiates, oxycodone and phencyclidine. Urine testing showed equivalent sensitivity to current meconium methods for detecting in utero exposure to amphetamines and cocaine.

8 April 2008 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
ARAnouk M. Rijs
Anouk M. Rijs
BCBridgit O. Crews
Bridgit O. Crews
MVMattanjah De Vries
Mattanjah De Vries
JHJeffrey S. Hannam
Jeffrey S. Hannam
DLDavid A. Leigh
David A. Leigh
WBWybren J. Buma
Wybren J. Buma

1 July 2015 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
BCBridgit O Crews
Bridgit O Crews
MPMatthew S. Petrie
Matthew S. Petrie
Methemoglobin, myoglobin, and methemalbumin can cause abnormal dark color in patient samples. "Lipemia" was measured at 660-and 700-nm wavelengths (1); therefore any compounds that absorb light in this range will result in an increased lipemic index. In this patient, methemoglobin was always Ͻ7.5% (cooximetry), myoglobin was not detected (gel filtration chromatography and mass spectrometry), but an interference causing falsely increased results by immunoturbidimetry was observed. Haptoglobin was undetectable (nephelometry). Methemalbumin, formed when albumin binds excess hemin (oxidized free heme), was markedly increased (multiwavelength spectrophotometry) (2, 3), consistent with intravascular hemolysis (4). Chemistry analyses were performed on both undiluted serum and serial dilutions to confirm acceptable analyte recovery and rule out potential interference (5).

13 March 2025 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
BCBridgit O. Crews
Bridgit O. Crews